Floatz logo

22 assets in Amyloidosis

Therapeutic assets addressing Amyloidosis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Acoramidis
Amyloidosis
BayerP4BBB (78)
Dexasone
Amyloidosis
Ascentage Pharma Group Inc.P3BB (70)
Empagliflozin
Amyloidosis
Columbia UniversityP4BB (69)
Tafamidis
Amyloidosis
PfizerP4BB (69)
Cyclophosphamide
Amyloidosis
University of Alabama at BirminghamP2BB (67)
Lenalidomide
Amyloidosis
Ascentage Pharma Group Inc.P3BB (67)
Enavogliflozin
Amyloidosis
Seoul St. Mary's HospitalP4BB (65)
Evuzamitide
Amyloidosis
National Institute of Allergy and Infectious Diseases (NIAID)P2BB (64)
Nexiguran Ziclumeran
Amyloidosis
Intellia TherapeuticsP3B (60)
Bortezomib
Amyloidosis
University of Alabama at BirminghamP2B (57)
Pomalidomide
Amyloidosis
Weill Medical College of Cornell UniversityP2B (57)
Daratumumab
Amyloidosis
Weill Medical College of Cornell UniversityP2CCC (53)
Donanemab
Amyloidosis
Eli Lilly and CompanyP2CCC (53)
Fapi-46
Amyloidosis
Nantes University HospitalP2CCC (53)
Genistein
Amyloidosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP1/2CCC (48)
Lisaftoclax
Amyloidosis
Ascentage Pharma Group Inc.P1/2CC (47)
Coramitug
Amyloidosis
Novo Nordisk A/SP1CC (43)
Pegfilgrastim
Amyloidosis
Memorial Sloan Kettering Cancer CenterP1CC (43)
Technetium Tc 99M Pyrophosphate
Amyloidosis
Mayo ClinicEarly P1CC (43)
Bcma Car T Cells
Amyloidosis
Zhejiang UniversityEarly P1C (39)
Selinexor
Amyloidosis
Weill Medical College of Cornell UniversityEarly P1C (39)
Dapagliflozin
Amyloidosis
National Medical Research Center for Cardiology, Ministry of Health of Russian FederationN/AD (30)